Table 1.
Characteristics of patients admitted for intracranial hemorrhage between January and June in 2019 and 2020, as well as in March/April in 2019 and 2020.
| Total Jan–June 2019 + Jan–June 2020 | March/April 2019 | Lockdown 2020 | |
|---|---|---|---|
| n = 320 | n = 54 | n = 33 | |
| Sex (male, n; %) | 191 (59.7) | 33 (61.1) | 21 (63.6) |
| Age (mean, range) | 69.4 (18–101) | 69.2 (30–96) | 68.4 (18–101) |
| Non-traumatic intracranial hemorrhage (n, %) | 138 (43.1) | 19 (35.2) | 11 (33.3) |
| ICH | 129 | 18 | 9 |
| IVH | 3 | 1 | 1 |
| SAH | 6 | 0 | 1 |
| Traumatic intracranial hemorrhage (n, %) | 182 (56.9) | 35 (64.8) | 22 (66.7) |
| cTBI | 35 | 4 | 8 |
| tICH | 36 | 8 | 4 |
| tSDH | 74 | 13 | 8 |
| tSAH | 31 | 7 | 2 |
| EDH | 6 | 3 | 0 |
| Anticoagulation (n, %) | 130 (40.6) | 19 (35.2) | 14 (42.4) |
| NOAC | 40 | 5 | 5 |
| Phenprocoumon | 16 | 3 | 2 |
| PAI | 64 | 9 | 7 |
| Dual PAI | 5 | 0 | 0 |
| Other* | 5 | 2 | 0 |
*
Enoxaparin, 3; Nadroparin, 1; Fondaparinux, 1.
ICH, intracerebral hemorrhage; IVH, intraventricular hemorrhage; SDH, subdural hematoma; SAH, non-aneurysmatic subarachnoid hemorrhage; cTBI, complex traumatic brain injury; tICH, traumatic intracerebral hemorrhage; tSDH, traumatic subdural hematoma; tSAH, traumatic subarachnoid hemorrhage; EDH, epidural hematoma; NOAC, non-vitamin K antagonist oral anticoagulants; PAI, platelet aggregation inhibitors.